Home / 2021 / March / 01

Daily Archives: March 1, 2021

Brunswick Exploration Options Nickel Property in Quebec

MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) — Brunswick Exploration Inc. (“BRW” or the “Company”) is pleased to announce that is has signed option and purchase agreements from a private company and prospectors to acquire a 100% interest in the Lac Édouard Nickel Project (“Lac Édouard” or the “Property”), located 40 km northeast of the town of La Tuque, Quebec, and 125 km northwest of Quebec City. Access to the site is by paved road and includes a significant nickel-copper mineralized mafic-ultramafic body that was last drilled in 1971 and which offers excellent exploration potential.

Mr. Killian Charles, President of BRW, commented: “We are very excited to announce this new greenfield nickel-copper project for the Company, especially in light of rising nickel and copper prices and projected high demand for nickel in a decarbonizing economy. The Lac Édouard system has not seen drilling since 1971, contains high-grade nickel sulfide mineralization, and fits very nicely with a Voisey’s Bay deposit model. Importantly, the feeder to the mineralized system has never been identified, and the system is open down-dip to the north and to the east. Furthermore, the historical mineralization was never assayed for platinum, palladium or cobalt. Potential extensions and feeders will be drill-tested as soon as permits can be obtained within the next 2 to 3 months.”

Lac Édouard Property Overview

The total Property package comprises 33 claims with a total surface area of 1838.5 hectares (18.4 square kilometres), is paved-road accessible and located within the Portneuf geological domain (Grenville Geological Province). Near-surface nickel mineralization was discovered in 1966 and the Property was drilled between 1967 and 1971 (total of 54 shallow holes), defining a small nickel deposit, which was further investigated with a small open pit extraction in 1972-1973. All drill holes were shallow (maximum vertical depth of 150 metres), and the best historical drill intersections (MERQ assessment files) include:

DDH LENGTH (m) Ni (%) Cu (%)
B2 6.4 2.00 0.51
B4 13.1 2.31 0.56
B3 14.3 1.33 0.52
B66-707 27.3 1.34 0.55

Exploration Targets

Historical records indicate no assays were done for cobalt nor platinum-palladium, and that all drilling was limited to a small area measuring 330 x 300 metres.

  • 3D geological modelling indicates the main intrusive system is open to the north (down-dip), open to the east, and a 2007 airborne geophysical survey indicates the presence of EM conductors stretching to the east from the known mineralized body.
  • Quebec government stream geochemical surveys indicate anomalies of up to 400 ppm Ni in sediments, located 1,100 metres north of the deposit. In addition, other ultramafic intrusive bodies on the Property have never been drilled.

The Property is considered highly prospective as the host layered intrusions include websterite, minor harzburgite and norite, as well as high-tenor mineralization (3-4% Ni in 100% sulfides). A Voisey’s Bay type metallogenic model applies well to this property, in that late-tectonic fertile mafic-ultramafic bodies intrude older sulfide-bearing gneiss/migmatite terranes and have presumably been fed by deeper mineralized magma conduits (chonoliths).

Option and Purchase Terms (All dollar figures in Canadian dollars)

Brunswick optioned 25 claims representing 1,374.5 hectares from Les Ressources Tectonic Inc. The option allows BRW to acquire a 100% interest in the Property over a three-year period for a total cash consideration of $170,000 and exploration expenditures of $500,000 under the following terms:

  • Upon closing of the formal agreement, Brunswick Exploration will pay $15,000 dollars;
  • Upon the first-year anniversary of the closing, Brunswick Exploration will pay $45,000 and will have completed $100,000 in exploration;
  • Upon the second-year anniversary of the closing, Brunswick Exploration will pay $50,000 and will have completed and additional $150,000 in exploration;
  • Upon the third-year anniversary of the closing, Brunswick Exploration will pay $60,000 and will have completed and additional $250,000 in exploration;

The schedule can be accelerated at BRW’s discretion. BRW has also granted a two percent (2%) NSR on the claims covered by the option agreement. The first half (1%) of the NSR may be repurchased upon payment of $1,500,000 from BRW to the optionor. BRW retains a first right of purchase of the second half of the NSR.

Additionally, the Company has purchased a 100% interest in 8 peripheral claims (464 hectares) to the optioned property from local prospectors for a cash consideration of $14,400. BRW has also granted a two percent (2%) NSR on the purchased claim. The first half (1%) of the NSR may be repurchased upon payment of $1,000,000 from BRW to the vendors. The second half may be purchased for $2,000,000. If BRW elects to complete both payments, it will have repurchased the entirety of the royalty on the eight purchased claims.

Corporate Update

Brunswick Exploration would like to announce a corporate website is now available at www.brwexplo.ca. Furthermore, following a request by the TSXV, the Company confirms that the number of flow-through shares issued on December 18, 2020 pursuant to the Company’s private placement was 9,082,344 flow-through shares at a price of $0.22 per flow-through share for gross proceeds of $1,998,116 instead of 9,122,344 flow-through shares for gross proceeds of $2,006,916 as announced in the Company’s press release dated December 21, 2020.

Qualified Person

The scientific and technical information contained in this press release has been reviewed and approved by Mr. Robert Wares, P. Geo, CEO of Brunswick Exploration.

About Brunswick Exploration

The Company, formerly Komet Resources Inc., is part of the Osisko Group of companies and is a Montreal-based mineral exploration venture listed on the TSX-V under symbol BRW. The Company has sold its former African assets and is now focused on exploration and development of gold and base metal properties in Eastern Canada. Current projects include gold-polymetallic vein systems in Southern New Brunswick (Fundy Gold Project), base metals VMS in the Bathurst Camp in northern New Brunswick and in the Chibougamau region of Quebec (Waconichi), and the new Lac Édouard nickel-copper project in Québec.

Investor Relations/information

Mr. Killian Charles, President (kcharles@BRWexplo.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Cautionary Statement on Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation based on expectations, estimates and projections as at the date of this news release. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, delays in obtaining or failures to obtain required governmental, environmental or other project approvals; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets; inflation; fluctuations in commodity prices; delays in the development of projects; the other risks involved in the mineral exploration and development industry; and those risks set out in the Corporation’s public documents filed on SEDAR at www.sedar.com. Although the Corporation believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

AIR to Make its Catastrophe Exposure Database Schema Available as an Open Standard

Insurance industry will be able to more easily transfer exposure data, increasing efficiency and use of analytics to make better risk management decisions

Boston, March 01, 2021 (GLOBE NEWSWIRE) — Catastrophe modeling firm AIR Worldwide today announced that it is making its Catastrophe Exposure Data Exchange (CEDETM) database schema available as an open standard in order to facilitate accurate, efficient and transparent data exchange throughout the insurance value chain, allowing companies to make better risk management decisions. AIR Worldwide is a Verisk (Nasdaq:VRSK) business.

“We applaud AIR’s decision to make CEDE an open standard and for their support of efforts to encourage open and transparent data standards in the insurance industry,” said Sean Ringsted, chief risk officer at Chubb. “Efficiency is critical in a competitive marketplace, and an open standard reduces friction, facilitates the transfer of data with our trading partners and encourages the use of analytics for all parties involved; ultimately improving service to our customers.”

“RenaissanceRe has been a strong supporter of increasing access to exposure data to build a more risk-resilient world.  We recognize AIR’s commitment to open data standards over the past three decades and we welcome this further evolution in their ongoing efforts to make data transfer as seamless as possible,” said Ian Branagan, EVP group chief risk officer at RenaissanceRe. “As the digital needs of the market evolve, there is a recognition across the industry that data standards benefit everyone and open source approaches such as AIR’s help facilitate richer business interactions.”

AIR has long been a proponent of open standards and in 1993 developed UNICEDE®, a globally accepted industry data format to standardize insurance data exchange. CEDE is the open database standard developed by AIR to facilitate accurate and transparent data exchange and to encourage model development. AIR’s open data license is based on Apache 2.0, which is recognized worldwide and promotes efficiency and interoperability. The open standards license allows AIR clients and partners to use the CEDE format as an internal repository which allows for better collaboration and innovation. Additionally, AIR actively supports the Open Exposure Data Format (OED) by freely providing its CEDE format as the database structure for models running on Oasis LMF, an open source nonprofit loss modeling framework.

“AIR’s exposure data schema is part of a broader industry call for open and transparent data formats, and we are proud to be a part of the solution by offering an open data standard,” said Bill Churney, president of Verisk’s AIR Worldwide. “Having an open data standard will allow the industry to adopt this common data format and more easily transfer exposure data across the insurance value chain.”

About AIR Worldwide
AIR Worldwide (AIR) provides risk modeling solutions that make individuals, businesses, and society more resilient to extreme events. In 1987, AIR Worldwide founded the catastrophe modeling industry and today models the risk from natural catastrophes, terrorism, pandemics, casualty catastrophes, and cyber incidents. Insurance, reinsurance, financial, corporate, and government clients rely on AIR’s advanced science, software, and consulting services for catastrophe risk management, insurance-linked securities, longevity modeling, site-specific engineering analyses, and agricultural risk management. AIR Worldwide, a Verisk (Nasdaq:VRSK) business, is headquartered in Boston, with additional offices in North America, Europe, and Asia. For more information, please visit www.air-worldwide.com.

About Verisk
Verisk (Nasdaq:VRSK) provides predictive analytics and decision-support solutions to customers in the insurance, energy and specialized markets, and financial services industries. More than 70 percent of the FORTUNE 100 relies on the company’s advanced technologies to manage risks, make better decisions and improve operating efficiency. The company’s analytic solutions address insurance underwriting and claims, fraud, regulatory compliance, natural resources, catastrophes, economic forecasting, geopolitical risks, as well as environmental, social and governance (ESG) matters. Celebrating its 50th anniversary, the company continues to make the world better, safer and stronger, and fosters an inclusive and diverse culture where all team members feel they belong. With more than 100 offices in nearly 35 countries, Verisk consistently earns certification by Great Place to Work. For more: Verisk.comLinkedInTwitterFacebook and YouTube.

For more information, contact:
Kevin Long
AIR Worldwide
+1-617-267-6645
klong@air-worldwide.com

Kevin Long
AIR Worldwide
+1-617-267-6645
klong@air-worldwide.com

 

AIR to Make its Catastrophe Exposure Database Schema Available as an Open Standard

Insurance industry will be able to more easily transfer exposure data, increasing efficiency and use of analytics to make better risk management decisions

Boston, March 01, 2021 (GLOBE NEWSWIRE) — Catastrophe modeling firm AIR Worldwide today announced that it is making its Catastrophe Exposure Data Exchange (CEDETM) database schema available as an open standard in order to facilitate accurate, efficient and transparent data exchange throughout the insurance value chain, allowing companies to make better risk management decisions. AIR Worldwide is a Verisk (Nasdaq:VRSK) business.

“We applaud AIR’s decision to make CEDE an open standard and for their support of efforts to encourage open and transparent data standards in the insurance industry,” said Sean Ringsted, chief risk officer at Chubb. “Efficiency is critical in a competitive marketplace, and an open standard reduces friction, facilitates the transfer of data with our trading partners and encourages the use of analytics for all parties involved; ultimately improving service to our customers.”

“RenaissanceRe has been a strong supporter of increasing access to exposure data to build a more risk-resilient world.  We recognize AIR’s commitment to open data standards over the past three decades and we welcome this further evolution in their ongoing efforts to make data transfer as seamless as possible,” said Ian Branagan, EVP group chief risk officer at RenaissanceRe. “As the digital needs of the market evolve, there is a recognition across the industry that data standards benefit everyone and open source approaches such as AIR’s help facilitate richer business interactions.”

AIR has long been a proponent of open standards and in 1993 developed UNICEDE®, a globally accepted industry data format to standardize insurance data exchange. CEDE is the open database standard developed by AIR to facilitate accurate and transparent data exchange and to encourage model development. AIR’s open data license is based on Apache 2.0, which is recognized worldwide and promotes efficiency and interoperability. The open standards license allows AIR clients and partners to use the CEDE format as an internal repository which allows for better collaboration and innovation. Additionally, AIR actively supports the Open Exposure Data Format (OED) by freely providing its CEDE format as the database structure for models running on Oasis LMF, an open source nonprofit loss modeling framework.

“AIR’s exposure data schema is part of a broader industry call for open and transparent data formats, and we are proud to be a part of the solution by offering an open data standard,” said Bill Churney, president of Verisk’s AIR Worldwide. “Having an open data standard will allow the industry to adopt this common data format and more easily transfer exposure data across the insurance value chain.”

About AIR Worldwide
AIR Worldwide (AIR) provides risk modeling solutions that make individuals, businesses, and society more resilient to extreme events. In 1987, AIR Worldwide founded the catastrophe modeling industry and today models the risk from natural catastrophes, terrorism, pandemics, casualty catastrophes, and cyber incidents. Insurance, reinsurance, financial, corporate, and government clients rely on AIR’s advanced science, software, and consulting services for catastrophe risk management, insurance-linked securities, longevity modeling, site-specific engineering analyses, and agricultural risk management. AIR Worldwide, a Verisk (Nasdaq:VRSK) business, is headquartered in Boston, with additional offices in North America, Europe, and Asia. For more information, please visit www.air-worldwide.com.

About Verisk
Verisk (Nasdaq:VRSK) provides predictive analytics and decision-support solutions to customers in the insurance, energy and specialized markets, and financial services industries. More than 70 percent of the FORTUNE 100 relies on the company’s advanced technologies to manage risks, make better decisions and improve operating efficiency. The company’s analytic solutions address insurance underwriting and claims, fraud, regulatory compliance, natural resources, catastrophes, economic forecasting, geopolitical risks, as well as environmental, social and governance (ESG) matters. Celebrating its 50th anniversary, the company continues to make the world better, safer and stronger, and fosters an inclusive and diverse culture where all team members feel they belong. With more than 100 offices in nearly 35 countries, Verisk consistently earns certification by Great Place to Work. For more: Verisk.comLinkedInTwitterFacebook and YouTube.

For more information, contact:
Kevin Long
AIR Worldwide
+1-617-267-6645
klong@air-worldwide.com

Kevin Long
AIR Worldwide
+1-617-267-6645
klong@air-worldwide.com

 

Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China

— Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas
— Junshi will continue to be responsible for the promotion of other indications in core areas
–The companies will continue to explore business collaborations in overseas markets including emerging markets

SHANGHAI, China, March 01, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Company has entered into an exclusive promotion agreement with AstraZeneca Pharmaceutical Co., Ltd. (“AstraZeneca Pharmaceutical” or the “Promoter”), pursuant to which Junshi Biosciences will grant AstraZeneca Pharmaceutical the exclusive promotion right of toripalimab in mainland China for the urothelial carcinoma indications to be approved subsequently for marketing and the exclusive promotion right for all indications approved and to be approved in non-core areas. Junshi Biosciences will continue to be responsible for the promotion of other indications approved and to be approved excluding urothelial carcinoma indications in core areas.

This strong alliance between the two companies will help promote local high-quality innovative drugs to benefit more Chinese patients. Junshi Biosciences and AstraZeneca will continue to explore overseas business collaboration including the emerging markets and actively explore the possibility of expanding the depth and breadth of future collaborations.

“We are delighted to work with AstraZeneca in the commercialization of Toripalimab in China,” said Dr. Ning Li, CEO of Junshi Biosciences. “We are confident that by leveraging the extensive networks AstraZeneca has established over the years, and especially by utilizing its ability to promote in the county-level markets, this innovative drug with excellent performance in efficacy and safety will achieve greater success in the Chinese market and will enable more patients to receive timely and effective treatment. Under the guidance of the company’s ‘In China, For Global’ strategy, we also look forward to more in-depth collaborations with AstraZeneca in a wider range of fields in order to provide better and more affordable treatment options to patients in China and all over the world.”

About Toripalimab
Toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in China. More than thirty company-sponsored clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States. On 17 December 2018, Toripalimab obtained a conditional approval from the the National Medical Products Administration (“NMPA”) for the second-line treatment of unresectable or metastatic melanoma. Toripalimab was included in the 2019 and 2020 Guidelines of Chinese Society of Clinical Oncology (CSCO) for the Diagnosis and Treatment of Melanoma. The supplemental NDA of Toripalimab for the second-line treatment of metastatic urothelial carcinoma was accepted by the NMPA in May 2020 and received priority review designations from the NMPA in July 2020. In September 2020, Toripalimab was granted Breakthrough Therapy Designation by the US Food and Drug Administration (“FDA”) for the treatment of recurrent/metastatic nasopharyngeal carcinoma. In December 2020, Toripalimab was successfully included in the updated National Reimbursement Drug List. In February 2021, the supplemental NDA application of Toripalimab in combination with chemotherapy for the first-line treatment of patients with advanced, recurrent or metastatic nasopharyngeal carcinoma was accepted by the NMPA. In the same month, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after failure of at least two lines of prior systemic therapy. Currently, Toripalimab has been granted 1 Breakthrough, 1 Fast Track, and 3 Orphan Drug Designations by the FDA for the treatment of mucosal melanoma, nasopharyngeal carcinoma, and soft tissue sarcoma.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 28 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2. JS016 administered with bamlanivimab has received Emergency Use Authorization (EUA) by US FDA in Feb 2021 for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. The JS016 program is a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Contact Information

IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Solebury Trout
Bob Ai
bai@soleburytrout.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

In 1st Day on Job, New WTO Chief Pushes for Fisheries Deal

GENEVA – The new head of the World Trade Organization threw her support behind long-fruitless efforts among member countries to agree on fisheries subsidies that could reduce overfishing, calling the efforts a top priority as she took office on Monday.

Director-General Ngozi Okonjo-Iweala, a Nigerian economist and former government minister, donned a mask and doled out elbow bumps — COVID-19 oblige — as she took up the job at WTO headquarters on the banks of Lake Geneva.

“I am coming into one of the most important institutions in the world and we have a lot of work to do,” said Okonjo-Iweala, 66, who is both the first woman and the first African to hold the job. “I feel ready to go.”

Negotiators have been tasked with striking an agreement that could help eliminate subsidies for illegal, unreported and unregulated fishing, and prohibit some fisheries subsidies that contribute to overcapacity and overfishing.

Member states of the WTO, which works to craft accords that can ensure smooth international trade, have struggled to reach an agreement on fisheries after roughly two decades of work. Okonjo-Iweala called for finalizing the negotiations “as soon as possible,” and credited Colombian ambassador Santiago Wills, who chairs the talks on fisheries subsidies, for his “really hard” work.

“My presence is to try and support him proactively to try and unblock the situation so he can complete the fantastic work he has been doing,” she said alongside Wills as they met with various advocacy groups outside the WTO gates. “It has been 20 years — and 20 years is enough.”

“Things are not easy when members are negotiating and there are still a lot of critical issues that need to be sorted out,” she said. “But we are hopeful.”

Wills said it was “music to my ears to see on the first day the (director general) comes here and makes a statement on the fisheries negotiations.”

Okonjo-Iweala’s first day also consisted of meeting staffers and attending her first meeting of the General Council, made up of top envoys from the trade body’s 164 member states. The closed-door council meeting was largely held by videoconference because of measures aimed to fight the pandemic.

Okonjo-Iweala’s victory in the race last fall was delayed largely because the U.S. administration under Donald Trump supported another candidate. Her appointment came through last month when the Biden administration cleared the way for her selection at the trade body, whose rules require consensus.

The WTO is facing headwinds such as rising protectionism. Its dispute settlement system has been blocked because the U.S. has almost singlehandedly prevented appointments to its Appellate Body — a rough equivalent to an appeals court.

Okonjo-Iweala said last month that “wide-ranging reforms” are needed, vowing that a first priority would be to address the economic and health consequences of the COVID-19 pandemic — such as by working to lift export restrictions on supplies and vaccines to get them distributed to countries in need.

Source: Voice of America

Vaccine Passports Could Soon Be Required for Travel in Europe

The European Union’s executive arm said Monday it will propose rules for a passport to allow those who have been vaccinated or recently tested for COVID-19 to travel for work or tourism throughout the region.

From her Twitter account, EU Commission President Ursula Von der Leyen said legislation will be presented later this month for the digital pass, which she called a “green pass,” that hopefully could help EU member nations rebuild their tourism industries.

Following last week’s EU summit, where the idea was first discussed, Von der Leyen said the vaccine certificate could be launched in three months’ time, and that the pass would uphold data protection standards.

“Green pass” is the term used in Israel for the digital or paper document issued to allow the bearer to prove they have been inoculated and can therefore enter entertainment, sporting and dining venues.

There is a debate, however, among EU member nations, with some arguing it may be premature to issue such “passports” as it’s unclear how much protection vaccines give against transmission.

Others have argued about the fairness of allowing only those who have had access to vaccines to travel while many others must still live under restrictions.

The commission said last week it would seek to avoid discrimination against citizens who have not received a vaccine.

Source: Voice of America

Vaccine Passports Could Soon Be Required for Travel in Europe

The European Union’s executive arm said Monday it will propose rules for a passport to allow those who have been vaccinated or recently tested for COVID-19 to travel for work or tourism throughout the region.

From her Twitter account, EU Commission President Ursula Von der Leyen said legislation will be presented later this month for the digital pass, which she called a “green pass,” that hopefully could help EU member nations rebuild their tourism industries.

Following last week’s EU summit, where the idea was first discussed, Von der Leyen said the vaccine certificate could be launched in three months’ time, and that the pass would uphold data protection standards.

“Green pass” is the term used in Israel for the digital or paper document issued to allow the bearer to prove they have been inoculated and can therefore enter entertainment, sporting and dining venues.

There is a debate, however, among EU member nations, with some arguing it may be premature to issue such “passports” as it’s unclear how much protection vaccines give against transmission.

Others have argued about the fairness of allowing only those who have had access to vaccines to travel while many others must still live under restrictions.

The commission said last week it would seek to avoid discrimination against citizens who have not received a vaccine.

Source: Voice of America